Summary. In Phase I of this study to 
Introduction
Of the many factors which affect litter size in pigs, the initial constraint is the ovulation rate which averages 15 (Blichfeldt & Almlid, 1982; King & Williams, 1984; Pope & First, 1985) . A direct relationship exists between the number of corpora lutea (CL) and the number of live embryos up to 14 as each additional corpus luteum from 3 to 18 was associated with an additional 0-756 embryo (WuetaL, 1987) .
In pigs as in other species, ovulation rate is limited by the number of follicles that mature to ovulation. Evidence has been presented for several species indicating that luteinizing hormone (LH) is causally related to development of preovulatory follicles and to the number of follicles which subsequently ovulate. Perhaps the most important direct evidence concerning LH and folli¬ cular recruitment is that LH administration during the oestrous cycle induces superovulation in the cyclic hamster and guinea-pig (Garza et ai, 1984) . Epostane, an orally active 3ß-hydroxysteroid dehydrogenase inhibitor in CL, interrupts progesterone synthesis and therefore its negative feed¬ back, resulting in increased circulating LH concentrations in cattle (Peters & Lamming, 1986) . In a subsequent report in sheep, inhibition of mid-luteal phase progesterone production with epostane resulted in a significant enhancement of both ovulation rate and lambing rate (Webb, 1987) .
Follicular recruitment for ovulation in pigs occurs between Days 14 and 16 of the oestrous cycle (Clark et ai, 1982; Foxcroft & Hunter, 1985) . For the present study, it was proposed that increased LH secretion resulting from epostane treatment during follicular recruitment and maturation would enhance ovulation rate in gilts. The dose-response inhibitory effects of epostane on progesterone secretion during the oestrous cycle in gilts were determined in Phase I. In Phase II epostane was given for 7 or 12 days before mating to measure the effects on ovulation rate and embryo numbers.
Materials and Methods
Prepubertal Yorkshire-Landrace cross-bred gilts weighing approximately 90 kg were selected for the study since this is the size at which oestrus can be reliably induced after exposure to adult boars. Gilts were housed in groups of 6-12 in indoor pens with free access to water and feed. They were acclimatized to the facilities for 1-3 weeks before study and exposure to boars. As gilts were identified in oestrus, they were randomly assigned to treatment groups.
Phase I. The 25 gilts were assigned across 5 groups and received 0 (sham control), 0-625, I-25, 2-5 (Fig. 1 ). Blood samples were put into tubes containing saturated sodium citrate (0-25 ml) and immediately centrifuged (1200 g). Plasma was stored at -20°C for hormone assays. Concentrations of plasma progesterone were determined by radioimmunoassay (RIA; Nara & First, 1981) using 125I-labelled progesterone (Amersham Corp., Chicago, IL, USA). The mean intra-assay coefficient of variation (CV) was 19-1% and the inter-assay CV was 17-5%. The lower limit of detection was 100 pg/ml using 50 pi plasma samples. To assess possible effects of epostane on adrenal steroidogenesis, plasma concentrations of cortisol were determined by RIA (Krey et ai, 1975 (Snedecor & Cochran, 1980) . Independent variables were treatment, gilt-within-treatment (error term for testing treatment effects), sampling time and interaction between treatment and sampling time. The difference in mean hormone concentration in the sham-treated control group from the overall mean for the other 4 groups with time after epostane treatment was compared by F-test (Snedecor & Cochran, 1980) . The difference between pre-treatment baseline and the average hormone level within 12 h after treatment (combined 4-, 8-and 12-h samples) in each group was evaluated by t test. Next the percentage change of hormone concentrations from baseline until within 12 h (combined 4-, 8-and 12-h samples) after treatment was calculated and epostane dose levels were transformed by square-root for fitting to a linear model (Neter et ai, 1983) . Log transformation of dose levels which is typically used in similar situations yielded lower R2 values and was not considered further.
In Phase II, the main effects of centre, dose level of epostane, treatment periods and appropriate interactions were evaluated using general linear model (GLM) procedures (SAS, 1985) (Table 2) and was dose related (P < 001, Fig. 3 (Table 2) were similar ( > 005) to those of the epostane treatment groups for Centre A (13 + 3-9) and Centre (12 + 4-6). The numbers of viable embryos were also similar between control and epostane treatment groups (Centre A, 12 ± 3-9 and Centre B, 11 ± 3-8; > 0-05). Overall, embryo number did not increase significantly after epostane treatment in either centre, although several groups had higher numbers than in the respective control groups ( Table 2) .
Ratio of implantation sites to corpora lutea. As shown in Table 2 , the ratio showed a general decline as the ovulation rate was increased by epostane treatment (P < 001). The overall mean for all 8 epostane treatment groups of 59-9% and 67-6% was significantly lower (P < 005) than for controls in Centres A and B, respectively, but the value was not significantly different (P > 005) for 7-and 12-day treatment periods (61-4% vs 58-2% in Centre A and 680% vs 66-9% in Centre B).
Embryonic résorption rate. The mean résorption rates across all 8 epostane treatment groups were 3-7% and 8-4% in Centres A and B, respectively, which were not significantly different (P > 0-05) from the control groups (30% and 3-4%).
Cysticfollicles. Although the proportion of gilts with cystic follicles was similar in control and epostane treatment groups (P > 005), the number (mean ± s.d.) of cystic follicles per gilt was higher (P < 005) with epostane treatment (12 + 5-2) than in controls (2 ± 0-7). ±4-7 14 + 3-9 12 ± 3-3 11 + 3-6 15 + 4-3 13 ± 3-6 13 + 3-7 10 ± 3-3 = 0-2995 12 ± 2-5 11 ± 4-0 14 ± 3-9 12 ± 3-7 10 ± 3-2 14 + 4-5 13 ± 3-9 13 ± 3-9 10 ± 31 
Discussion
The present study clearly shows that epostane treatment significantly increases ovulation rate in gilts. This is the first demonstration that this inhibitor of progesterone secretion will cause an enhancement of ovulation rate in a multiple ovulating species with a magnitude similar to the effect described previously in sheep (Webb, 1987) . The enhancement of ovulation rate in gilts was due to consistent increases of 1-6 more corpora lutea after epostane treatment in 90% of the pregnant gilts, rather than to only some gilts showing excessive numbers of ovulations (Hunter, 1980 (Clark et ai, 1982; Foxcroft & Hunter, 1985; Foxcroft, 1987 Overall, the number of viable embryos was not significantly increased after epostane treatment. Ovulation rate among epostane groups increased proportionately more than the number of viable embryos, resulting in a lower ratio of number of viable implantation sites to number of CL. This is consistent with previous studies relating increased litter size to increased ovulation rate (Wu et ai, 1987) .
In some of the non-pregnant gilts, gross ovarian morphological changes and large cystic fol¬ licles were observed at slaughter. At Centre A, 5 gilts failed to exhibit oestrus within 36 days after treatment. Several other epostane-treated gilts (N = 7) showed oestrus, but remained anovulatory and their ovaries contained cystic follicles with thickened walls. These observations may explain why conception rate tended to be lower in these groups. Since epostane treatment continued until the expected day of oestrus, the normal steroidal processes of final follicular development may have been impaired and thereby contributed to the incidence of cystic follicles. Cessation of treatment a few days earlier before ovulation may be expected to result in less interference with follicular devel¬ opment and fertility, while still increasing ovulation rate. Variability in conception rates may also reflect artificial insemination as compared to natural mating.
Oral administration of epostane inhibited progesterone secretion as described for sheep (Ashworth et ai, 1987; Webb, 1987) and pigs (Martin et ai, 1987) . Plasma progesterone concen¬ trations had declined 4 h after feeding epostane, with recovery having begun at 12 h. The inhibitory effect of oral epostane administration on plasma progesterone concentrations was dose related. In Phase I, epostane significantly reduced progesterone production, but did not appear to shorten the normal lifespan of the CL as reflected by plasma progesterone values. Oestrous cycle length was not altered by epostane treatment in Phase II. Thus, the inhibitory effect of epostane on progesterone production is due to enzymic inhibition and does not appear to alter the timing of luteolysis. Epostane treatment did not significantly alter cortisol secretion, even though adrenal progesterone is the precursor.
The mechanism by which epostane enhanced ovulation rate has not been established. Epostane acts on CL to inhibit competitively progesterone production, thereby altering the negative feedback equilibrium and leading to increased LH secretion in cattle (Peters & Lamming, 1986) . We propose that increased LH secretion is then responsible for recruitment of more follicles to develop for ovulation, as demonstrated previously by the effects of LH or epostane in other species (Garza et ai, 1984; Webb, 1987) . A detailed analysis of the secretion patterns for LH, FSH, oestradiol and progesterone and their interrelationships during Phase II of the present study will be reported separately.
